Marco Gottardis
22Patents
7h-index
48Co-inventors
69Inventor score
Filing activity: Apr 21, 2000 → Sep 13, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8221765B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 63 | Active |
| US6960474B2 | Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator | Human Necessities | 61 | Expired |
| US8343501B2 | Bispecific EGFR/IGFIR binding molecules | Chemistry; Metallurgy | 41 | Active |
| US8728483B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 36 | Active |
| US9017655B2 | Bispecific EGFR/IGFIR binding molecules | Chemistry; Metallurgy | 34 | Active |
| US9902762B2 | Multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 27 | Active |
| US9771411B2 | Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules | Chemistry; Metallurgy | 22 | Active |
| US10183987B2 | Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules | Chemistry; Metallurgy | 7 | Active |
| US11207311B2 | Method of treating prostate cancer | Human Necessities | 5 | Active |
| US6624154B1 | Compositions and methods for treatment of hyperproliferative diseases | Human Necessities | 5 | Expired |
| US10774130B2 | Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins | Chemistry; Metallurgy | 4 | Active |
| US8492328B2 | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators | Chemistry; Metallurgy | 4 | Active |
| US7655688B2 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Human Necessities | 3 | Active |
| US10954286B2 | Bispecific EGFR/IGFIR binding molecules | Chemistry; Metallurgy | 1 | Active |
| US11793843B2 | Prostate neoantigens and their uses | Chemistry; Metallurgy | 0 | Active |
| US11986470B2 | Methods of treating prostate cancer | Human Necessities | 0 | Active |
| US11992486B2 | Methods of treating prostate cancer | Human Necessities | 0 | Active |
| US11986469B2 | Methods of treating prostate cancer | Human Necessities | 0 | Active |
| US11986468B2 | Methods of treating prostate cancer | Human Necessities | 0 | Active |
| US7138246B2 | Methods for identifying or screening for agents that modulate 17β-HSD3 | Physics | 0 | Expired |
| US7199227B2 | Polynucleotides encoding human histone deacetylase HDAC9c | Human Necessities | 0 | Expired |
| US12383543B2 | Methods of treating prostate cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.